Metabolic/Obesity Phase 3 Deal Benchmarks — Japan (2026)

Median upfront of $111M with total deal values reaching $514M in Japan territory.

Median Upfront

$111M

Total Deal Value

$411M

Royalty Range

9%–14.6%

Territory Multiplier

0.09x

Understanding Metabolic/Obesity Deal Benchmarks at Phase 3

Phase 3 Metabolic/Obesity licensing deals in Japan territory command a median upfront payment of $111M, with values ranging from $72M at the low end to $144M for premium assets. These benchmarks reflect the risk-adjusted value of clinical-stage assets in the metabolic/obesity therapeutic area, where development costs, competitive dynamics, and market potential all factor into deal pricing.

Total deal values — including milestones for development, regulatory, and commercial achievements — range from $308M to $514M, with a median of $411M. Royalty rates for metabolic/obesity assets at this stage typically fall between 9% and 14.6% of net sales, reflecting the balance between licensor value contribution and licensee commercialization investment.

The Japan territory applies a 0.09x multiplier to base deal economics. This accounts for market size, regulatory complexity, pricing environment, and competitive landscape differences across geographies. Licensors negotiating japan rights should calibrate upfront expectations and milestone structures accordingly.

PRO

Full Market Analysis

Detailed deal economics, territory impact analysis, and royalty structure breakdown.

We'll email you the full benchmark data for this page. No spam, unsubscribe anytime.

Unlock Everything — $299/mo Pro

7-day money-back guarantee · Cancel anytime

Full Benchmark Data

PRO

Full Benchmark Table

Low, median, and high ranges for upfront payments, total deal values, and royalty rates.

We'll email you the full benchmark data for this page. No spam, unsubscribe anytime.

Unlock Everything — $299/mo Pro

7-day money-back guarantee · Cancel anytime

Comparable Deals

PRO

See All Comparable Deals

View 0 comparable Metabolic/Obesity transactions with upfront payments, total values, and deal structures.

We'll email you the full benchmark data for this page. No spam, unsubscribe anytime.

Unlock Everything — $299/mo Pro

7-day money-back guarantee · Cancel anytime

Frequently Asked Questions

What is the average upfront payment for Phase 3 Metabolic/Obesity deals in Japan territory?

The median upfront payment for Phase 3 Metabolic/Obesity licensing deals in Japan territory is $111M, based on our analysis of comparable transactions. Values range from $72M for early-stage or less differentiated assets up to $144M for premium programs with strong clinical data or first-in-class mechanisms.

How does Japan territory affect Metabolic/Obesity deal value?

Japan rights carry a 0.09x multiplier relative to base deal economics. This means japan metabolic/obesity deals are valued at a discount compared to single-country rights, reflecting the combined market opportunity, regulatory pathway, and competitive dynamics of the territory.

What royalty rates are typical for Phase 3 Metabolic/Obesity licensing?

Royalty rates for Phase 3 metabolic/obesity assets typically range from 9% to 14.6% of net sales. The exact rate depends on the licensor's contribution (IP, clinical data, manufacturing), deal structure (exclusive vs. co-exclusive), and the licensee's commercialization investment. Higher royalties often correspond to lower upfront payments, and vice versa.

PRO

More Expert Insights

Territory impact analysis, royalty negotiation strategies, and deal structure guidance.

We'll email you the full benchmark data for this page. No spam, unsubscribe anytime.

Unlock Everything — $299/mo Pro

7-day money-back guarantee · Cancel anytime

Related Benchmarks

$7M upfront

Metabolic/Obesity · Preclinical · Japan

$21M upfront

Metabolic/Obesity · Phase 1 · Japan

$53M upfront

Metabolic/Obesity · Phase 2 · Japan

$314M upfront

Metabolic/Obesity · Approved · Japan

$65M upfront

Oncology · Phase 3 · Japan

$46M upfront

Neurology/CNS · Phase 3 · Japan

$81M upfront

Immunology · Phase 3 · Japan

$1.2B upfront

Metabolic/Obesity · Phase 3 · Global

Explore More

All Metabolic/Obesity Deals

View full therapeutic area benchmarks

Licensing Benchmarks Guide

2026 data from 1,900+ deals

Royalty Rate Benchmarks

Negotiation strategies by phase & modality

Run Custom Analysis

Pre-filled with Metabolic/Obesity · Phase 3

Run Your Own Benchmark

These benchmarks are starting points. Get a customized valuation for your specific asset, indication, and deal structure.

Open Deal Calculator

Cite This Data

APA

Ambrosia Ventures. (2026). Metabolic/Obesity Phase 3 Deal Benchmarks — Japan (2026). Retrieved from https://calculator.ambrosiaventures.co/data/metabolic-phase-3-deals-japan

HTML

<a href="https://calculator.ambrosiaventures.co/data/metabolic-phase-3-deals-japan">Metabolic/Obesity Phase 3 Deal Benchmarks — Japan (2026)</a> — Ambrosia Ventures (2026)

Embed Chart

Data sourced from 1,900+ verified biopharma transactions. Updated monthly.

Metric	Low	Median	High
Upfront Payment	$72M	$111M	$144M
Total Deal Value	$308M	$411M	$514M
Royalty Rate	9%	—	14.6%